Characteristics of unpublished registered studies: non‐replicating viral vector (73 studies)
Registration number	Registration date	Status	Design	Interventions	Estimated sample size	Phase
NCT04690387	30 December 2020	Completed	Adaptive	AV‐COVID‐19	27	Phase 1
ChiCTR2000031781	10 April 2020	Not recruiting	Parallel	Recombinant novel coronavirus (2019‐ncov) vaccine (adenovirus vector)	500	Phase 2
CTRI/2021/02/031295	15 February 2021	Not recruiting	Parallel	BBV154	175	Phase 1
CTRI/2021/05/033665	18 May 2021	Not recruiting	Parallel	COVID‐Vac Combined Vector Vaccine	228	Phase 3
NCT04398147	21 May 2020	Not recruiting	Adaptive	Ad5‐nCoV	696	Phase 1/Phase 2
NCT04509947	12 August 2020	Not recruiting	Parallel	Ad26.COV2.S	250	Phase 1
NCT04540419	7 September 2020	Not recruiting	Parallel	Ad5‐nCoV	500	Phase 3
NCT04564716	25 September 2020	Not recruiting	Parallel	Gam‐COVID‐Vac	100	Phase 3
NCT04614948	4 November 2020	Not recruiting	Parallel	Ad26.COV2.S	30,000	Phase 3
NCT04640233	23 November 2020	Not recruiting	Adaptive	Gam‐COVID‐Vac	1600	Phase 2/Phase 3
NCT04642339	24 November 2020	Not recruiting	Parallel	Gam‐COVID‐Vac	2000	Phase 3
NCT04656613	7 December 2020	Not recruiting	Parallel	Gam‐COVID‐Vac	1000	Phase 3
NCT04679909	22 December 2020	Not recruiting	Parallel	AdCOVID	180	Phase 1
NCT04751682	12 February 2021	Not recruiting	Parallel	BBV154	175	Phase 1
NCT04760730	18 February 2021	Not recruiting	Parallel	ChAdOx1 nCoV‐19 + rAd26‐S	100	Phase 1/Phase 2
NCT04791423	10 March 2021	Not recruiting	Parallel	GRAd‐COV2	10,300	Phase 2/Phase 3
NCT04840992	12 April 2021	Not recruiting	Parallel	Ad5‐nCoV	840	Phase 1/Phase 2
NCT04843722	13 April 2021	Not recruiting	Sequential assignment	hAd5‐S‐Fusion/N‐ETSD vaccine	540	Phase 1/Phase 2
NCT04845191	14 April 2021	Not recruiting	Sequential assignment	hAd5‐S‐Fusion/N‐ETSD vaccine	540	Phase 1/Phase 2
NCT04894305	20 May 2021	Not recruiting	Parallel	Ad26.COV2.S	380	Phase 1
NCT04895449	20 May 2021	Not recruiting	Parallel	MVA‐SARS‐2‐S	240	Phase 1/Phase 2
NCT04977024	26 July 2021	Not recruiting	Parallel	COH04S1	240	Phase 2
PACTR202104601572565	12 April 2021	Not recruiting	Parallel	Sputnik light vaccine	2200	Phase 3
NCT05011526	18 August 2021	Not recruiting	Parallel	ChAdOx1 nCoV‐19	1020	Phase 3
NCT05027672	30 August 2021	Not recruiting	Parallel	Gam‐COVID‐Vac	348	Phase 2
NCT05030974	1 September 2021	Not recruiting	Parallel	Ad26.COV2.S vaccine	460	Phase 4
NCT04998240	10 August 2021	Not recruiting	Parallel	BBIBP‐CorV + ChAdOx1 nCoV‐19	360	Phase 2
TCTR20210717002	17 July 2021	Not recruiting	Parallel	ChAdOx1 nCoV‐19 + CoronaVac	165	Phase 4
TCTR20210903006	3 September 2021	Not recruiting	Sequential assignment	ChAdOx1 nCoV‐19 + CoronaVac	80	Phase 1/Phase 2
TCTR20210904004	4 September 2021	Not recruiting	Sequential assignment	ChAdOx1 nCoV‐19 + inactivated COVID‐19 vaccine	40	Phase 1/Phase 2
NCT05091307	25 October 2021	Not recruiting	Parallel	Ad26.COV2.S + influenza vaccine	1680	Phase 3
NCT04833101	6 April 2021	Not recruiting	Parallel	Ad5‐nCoV + ZF2001	120	Phase 4
NCT05048940	17 September 2021	Not recruiting	Parallel	Ad26.COV2.S	386	Phase 3
NCT05049226	20 September 2021	Not recruiting	Parallel	ChAdOx1 nCoV‐19	1320	Phase 2
ChiCTR2100049530	2 August 2021	Not recruiting	Parallel	ChAdTS‐S	360	Phase 2
TCTR20210907003	7 September 2021	Not recruiting	Sequential assignment	ChAdOx1 nCoV‐19	60	Phase 1/Phase 2
TCTR20211004005	4 October 2021	Not recruiting	Parallel	ChAdOx1 nCoV‐19	300	Phase 2
NCT04730895	29 January 2021	Not recruiting	Parallel	ChAdOx1 nCoV‐19	360	Phase 1/Phase 2
NCT05094609	26 October 2021	Not recruiting	Parallel	Ad5‐triCoV/Mac	30	Phase 1
NCT05007496	16 August 2021	Not recruiting	Parallel	AV‐COVID‐19	145	Phase 2
EUCTR2020‐005226‐28‐IT	23 November 2020	Ongoing	Parallel	ChAdOx1 nCoV‐19	40,000	Phase 3
ChiCTR2100044249	12 March 2021	Ongoing	Adaptive	Ad5‐nCoV	40,000	Phase 3
EUCTR2020‐002584‐63‐DE	12 August 2020	Ongoing	Parallel	Ad26.COV2.S	225	Phase 2
EUCTR2020‐005801‐14‐PL	30 December 2020	Ongoing	Parallel	Ad26.COV2.S	570	Phase 3
EUCTR2021‐002693‐10‐AT	19 May 2021	Ongoing	Parallel	ChAdOx1 nCoV‐19	150	Phase 2
ISRCTN73765130	13 May 2021	Ongoing	Adaptive	ChAdOx1 nCoV‐19	2886	Phase 2
NCT04526990	26 August 2020	Ongoing	Adaptive	Ad5‐nCoV	40,000	Phase 3
NCT04536051	2 September 2020	Ongoing	Sequential assignment	ChAdOx1 nCoV‐19	10,300	Phase 3
NCT04639466	20 November 2020	Ongoing	Parallel	COH04S1	129	Phase 1
NCT04666012	14 December 2020	Ongoing	Sequential assignment	AdCLD‐CoV19	150	Phase 1/Phase 2
NCT04684446	24 December 2020	Ongoing	Parallel	ChAdOx1 nCoV‐19 + rAd26‐S	100	Phase 1/Phase 2
NCT04741061	5 February 2021	Ongoing	Parallel	Sputnik light vaccine	6000	Phase 3
NCT04776317	1 March 2021	Ongoing	Parallel	ChAdV68‐S‐TCE	140	Phase 1
NCT04816019	25 March 2021	Ongoing	Sequential assignment	ChAdOx1 nCoV‐19	54	Phase 1
NCT04830800	5 April 2021	Ongoing	Parallel	COVIVAC	420	Phase 1/Phase 2
NCT04916886	8 June 2021	Ongoing	Parallel	Ad5‐nCoV	2016	Not reported
NCT04952727	7 July 2021	Ongoing	Parallel	Ad5‐nCoV	300	Phase 4
NCT04954092	8 July 2021	Ongoing	Sequential assignment	Gam‐COVID‐Vac M	350	Phase 2/Phase 3
NCT04962906	15 July 2021	Ongoing	Parallel	Gam‐COVID‐Vac + ChAdOx1 nCov‐19	150	Phase 2
NCT04973449	22 July 2021	Ongoing	Parallel	ChAdOx1 nCov‐19	2475	Phase 2/Phase 3
PACTR202006922165132	22 June 2020	Ongoing	Parallel	ChAdOx1 nCoV‐19	2000	Phase 1/Phase 2
NCT04983537	30 July 2021	Ongoing	Parallel	Gam‐COVID‐Vac	120	Phase 2
NCT04988048	3 August 2021	Ongoing	Parallel	Gam‐COVID‐Vac + ChAdOx1 nCov‐19	1760	Phase 2
NCT05007951	17 August 2021	Ongoing	Parallel	ChAdOx1 nCov‐19	3990	Phase 3
NCT05005156	13 August 2021	Ongoing	Parallel	Ad5‐nCoV	876	Phase 2
EUCTR2019‐003102‐26‐IT	7 June 2021	Ongoing	Parallel	ChAdOx1 nCov‐19	33	Phase 1/Phase 2
NCT05054621	23 September 2021	Ongoing	Parallel	ChAdOx1 nCoV‐19 + MVC‐COV1901	110	Phase 2
EUCTR2021‐001978‐37‐ES	6 May 2021	Ongoing	Adaptive	ChAdOx1 nCoV‐19 + BNT162b2	600	Phase 2
NCT05037188	8 September 2021	Ongoing	Sequential assignment	BCD‐250	160	Phase 1/Phase 2
NCT05067933	5 October 2021	Ongoing	Sequential assignment	VXA‐CoV2‐1.1‐S	896	Phase 2
TCTR20210722003	22 July 2021	Ongoing	Parallel	ChAdOx1 nCov‐19	400	Phase 2
NCT04685603	25 December 2020	Ongoing	Adaptive	AV‐COVID‐19	27	Phase 1
NCT04535453	2 September 2020	Cancelled	Parallel	Ad26.COV2.S	1210	Phase 2